FDA nod for second COVID-19 booster jab in older and immunocompromised patients

30 March 2022

The US Food and Drug Administration (FDA) has authorized a second booster dose of either the Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) or the Moderna COVID-19 vaccines for older people and certain immunocompromised patients.

This follows the FDA’s previous authorization of a single booster dose for certain immunocompromised individuals following completion of a three-dose primary vaccination series.

"Current evidence suggests some waning of protection over time against serious outcomes from COVID-19 in older and immunocompromised individuals"Under the amended emergency use authorizations, a second booster dose of one of the two mRNA vaccines may be administered to people 50 years of age and older at least four months after receipt of a first booster.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK